Modulation of calcium-binding proteins expression and cisplatin chemosensitivity by calcium chelation in human breast cancer MCF-7 cells.
BAPTA-AM
Calcium-binding proteins
Cisplatin
Intracellular calcium
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
29
08
2020
revised:
21
12
2020
accepted:
15
01
2021
entrez:
3
2
2021
pubmed:
4
2
2021
medline:
4
2
2021
Statut:
epublish
Résumé
Cisplatin (CDDP) is currently one of the most effective FDA-approved treatments for breast cancer. Previous studies have shown that CDDP-induced cell death in human breast cancer (MCF-7) cells is associated with disruption of calcium homeostasis. However, whether the sensitivity of breast cancer cells to cisplatin is associated with dysregulation of the expression of calcium-binding proteins (CaBPs) remains unknown. In this study, we evaluated the effect of the intracellular calcium chelator (BAPTA-AM) on viability of MCF-7 cells in the presence of toxic and sub-toxic doses of cisplatin. Furthermore, this study assessed the expression of CaBPs, calmodulin, S100A8, and S100A14 in MCF-7 cells treated with cisplatin. Cell viability was determined using MTT-based in vitro toxicity assay. Intracellular calcium imaging was done using Fluo-4 AM, a cell-permeant fluorescent calcium indicator. Expression of CaBPs was tested using real-time quantitative PCR. Exposure of cells to increasing amounts of CDDP correlated with increasing fluorescence of the intracellular calcium indicator, Fluo-4 AM. Conversely, treating cells with cisplatin significantly decreased mRNA levels of calmodulin, S100A8, and S100A14. Treatment of the cells with calcium chelator, BAPTA-AM, significantly enhanced the cytotoxic effects of sub-toxic dose of cisplatin. Our results indicated a statistically significant negative correlation between calmodulin, S100A8, and S100A14 expression and sensitivity of breast cancer cells to a sub-toxic dose of cisplatin. We propose that modulating the activity of calcium-binding proteins, calmodulin, S100A8, and S100A14, could be used to increase cisplatin efficacy, lowering its treatment dosage while maintaining its chemotherapeutic value.
Identifiants
pubmed: 33532651
doi: 10.1016/j.heliyon.2021.e06041
pii: S2405-8440(21)00146-8
pmc: PMC7829211
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e06041Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cell Calcium. 2018 Mar;70:3-15
pubmed: 28801101
J Biol Chem. 2012 Sep 14;287(38):31666-73
pubmed: 22822055
J Biol Chem. 2014 Jan 10;289(2):827-37
pubmed: 24285542
Oncol Rep. 2015 Dec;34(6):3051-60
pubmed: 26398138
Cell Oncol. 2009;31(4):301-15
pubmed: 19633366
Nature. 1999 Jan 21;397(6716):259-63
pubmed: 9930701
Endocr Rev. 2003 Dec;24(6):719-36
pubmed: 14671000
BMC Pharmacol Toxicol. 2020 Mar 2;21(1):19
pubmed: 32122396
Neurotoxicology. 2009 Mar;30(2):194-202
pubmed: 19118571
Breast Cancer Res Treat. 2009 Jun;115(3):545-60
pubmed: 18587642
EMBO J. 1987 Dec 20;6(13):3961-8
pubmed: 2832147
J Biol Chem. 2001 Sep 21;276(38):35676-83
pubmed: 11470795
Cell. 2007 Dec 14;131(6):1047-58
pubmed: 18083096
J Clin Endocrinol Metab. 2015 Feb;100(2):E232-42
pubmed: 25423568
Biochim Biophys Acta. 2014 Feb;1843(2):398-435
pubmed: 24188867
Front Pharmacol. 2012 Apr 25;3:67
pubmed: 22539925
J Toxicol Sci. 2014;39(5):765-74
pubmed: 25242407
Br J Cancer. 2003 Apr 22;88(8):1199-206
pubmed: 12698184
Front Oncol. 2018 Nov 05;8:496
pubmed: 30456203
Oncol Lett. 2016 Apr;11(4):2411-2419
pubmed: 27073489
Cancer Res. 2002 Dec 1;62(23):6823-6
pubmed: 12460893
Oncogene. 2002 Jun 20;21(27):4266-76
pubmed: 12082614
Oncotarget. 2018 Jun 26;9(49):29064-29081
pubmed: 30018736
Physiol Rev. 1997 Oct;77(4):901-30
pubmed: 9354808
Annu Rev Biochem. 1987;56:159-93
pubmed: 3304132
J Biol Chem. 2000 Apr 14;275(15):11470-7
pubmed: 10753965
J Cell Biochem. 2018 Jul;119(7):6216-6230
pubmed: 29663486
Nat Rev Cancer. 2008 May;8(5):361-75
pubmed: 18432251
Oncogene. 2001 Apr 5;20(15):1803-15
pubmed: 11313928
Oncol Lett. 2016 Mar;11(3):1936-1942
pubmed: 26998104
Oncotarget. 2017 Apr 4;8(14):22876-22893
pubmed: 28206967
BMC Cancer. 2011 Sep 21;11:399
pubmed: 21933447
Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):19-24
pubmed: 16415424
Neurotoxicology. 2009 Sep;30(5):803-10
pubmed: 19465052
Int J Mol Med. 2012 Jan;29(1):65-72
pubmed: 21971985
Biophys J. 2000 Apr;78(4):1906-20
pubmed: 10733970
Biochem Cell Biol. 2004 Aug;82(4):508-15
pubmed: 15284904
Front Cell Neurosci. 2017 Oct 27;11:338
pubmed: 29163050
Kidney Int. 2009 Sep;76(6):604-13
pubmed: 19536080
Cell. 1993 Nov 19;75(4):817-25
pubmed: 8242752
Br J Pharmacol. 2007 Aug;151(8):1176-86
pubmed: 17592515
Electrophoresis. 1999 Apr-May;20(4-5):1047-54
pubmed: 10344284
Aging Dis. 2016 May 27;7(3):254-66
pubmed: 27330840
Cancers (Basel). 2011 Mar 15;3(1):1351-71
pubmed: 24212665
Cell. 1995 Jan 27;80(2):259-68
pubmed: 7834745
Mol Cell. 2017 Jun 15;66(6):780-788
pubmed: 28622523
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722137
J Clin Invest. 2010 Oct;120(10):3594-605
pubmed: 20811155
Cell. 2012 Jul 6;150(1):165-78
pubmed: 22770218
Indian J Cancer. 2014 Mar;51 Suppl 3:e67-71
pubmed: 25818737
Oncol Rep. 2014 Jan;31(1):248-54
pubmed: 24173208
Br J Cancer. 1991 Mar;63(3):346-7
pubmed: 2003974
Cancer Res. 1982 Jul;42(7):2571-4
pubmed: 7083150
Gynecol Oncol. 1989 Nov;35(2):156-8
pubmed: 2807005
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72
pubmed: 12011455
J Biol Chem. 2001 Feb 23;276(8):5613-21
pubmed: 11096083
J Clin Invest. 1998 Feb 15;101(4):777-82
pubmed: 9466972
Int J Cancer. 1994 Jun 1;57(5):684-90
pubmed: 8194876
Biosci Rep. 2000 Jun;20(3):129-38
pubmed: 11095113
J Clin Oncol. 1986 Jun;4(6):994-1012
pubmed: 2423656
BMC Cancer. 2015 Feb 13;15:53
pubmed: 25884418
Nat Rev Cancer. 2011 Jul 22;11(8):609-18
pubmed: 21779011
Am J Physiol Renal Physiol. 2011 May;300(5):F1171-9
pubmed: 21325496